AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Syntara Ltd

0.026

0.000-1.89%

Volume:704.11K

Turnover:18.09K

Market Cap:51.01M

PE:-3.59

High:0.026

Open:0.026

Low:0.025

Close:0.027

52wk High:0.040

52wk Low:0.019

Shares:1.96B

Float Shares:1.00B

Volume Ratio:0.95

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.007

EPS(LYR):-0.005

ROE:-90.51%

ROA:-47.51%

PB:4.81

PE(LYR):-4.82

Loading ...

Overview Company News Filings

Syntara Ltd - Trading Halt Pending Announcement on FDA Correspondence for Amsulostat Phase 2B Trial Protocol

THOMSON REUTERS

Syntara's Myelofibrosis Drug Candidate Shows 'Significant' Commercial Potential, Euroz Hartleys Says

MT Newswires Live

Syntara Receives Nearly AU$2 Million Milestone Payment from UK Charity

MT Newswires Live

Syntara's Pancreatic Cancer Drug Candidate to be Subject of Australian Government-Funded Clinical Study

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/SNT.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SNT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SNT.AU\",,,,,undefined,":{"symbol":"SNT.AU","market":"AU","secType":"STK","nameCN":"Syntara Ltd","latestPrice":0.026,"timestamp":1787292720000,"preClose":0.0265,"halted":0,"volume":704106,"delay":0,"changeRate":-0.018867924528301903,"nameEN":"Syntara Ltd","floatShares":1004676595,"shares":1961906275,"eps":-0.007236,"marketStatus":"Not Yet Opened","change":-0.0005,"latestTime":"08-21 16:12:00 AEST","open":0.026,"high":0.026,"low":0.025,"amount":18090,"amplitude":0.037736,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.007236,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.0265,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.9477915472498059,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"SNT.AU","preClose":0.0265,"auctionPrice":0.026,"auctionVolume":1238,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292035822}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SNT.AU\",,,,,undefined,":{"symbol":"SNT.AU","floatShares":1004676595,"roa":"-47.51%","roe":"-90.51%","lyrEps":-0.005389,"volumeRatio":0.9477915472498059,"shares":1961906275,"dividePrice":0,"high":0.026,"amplitude":0.037736,"preClose":0.0265,"low":0.025,"week52Low":0.019,"pbRate":"4.81","psRate":"6.80","week52High":0.04,"institutionHeld":0,"latestPrice":0.026,"eps":-0.007236,"divideRate":0,"volume":704106,"delay":0,"ttmEps":-0.007236,"open":0.026,"prevYearClose":0.035,"prevWeekClose":0.026,"prevMonthClose":0.025,"prevQuarterClose":0.02,"fiveDayClose":0.026,"twentyDayClose":0.022,"sixtyDayClose":0.026},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNT.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-07-28","symbol":"SNT.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1785160800000,"reportTimeType":"","actualEps":null},{"date":"2025-05-01","symbol":"SNT.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1746057600000,"name":null,"time":"","dateTimestamp":1746021600000,"actualEps":null},{"market":"AU","date":"2024-10-29","symbol":"SNT.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1730120400000,"reportTimeType":"pre","actualEps":null},{"date":"2024-04-30","symbol":"SNT.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1714435200000,"name":null,"time":"","dateTimestamp":1714399200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNT.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2630476334","title":"Syntara Ltd - Trading Halt Pending Announcement on FDA Correspondence for Amsulostat Phase 2B Trial Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2630476334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630476334?lang=en_us&edition=fundamental","pubTime":"2026-04-27 07:22","pubTimestamp":1777245767,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nFWN4171CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNT.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628349224","title":"Syntara's Myelofibrosis Drug Candidate Shows 'Significant' Commercial Potential, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2628349224","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628349224?lang=en_us&edition=fundamental","pubTime":"2026-04-17 11:58","pubTimestamp":1776398301,"startTime":"0","endTime":"0","summary":"Syntara's (ASX:SNT) Amsulostat drug candidate has a \"unique\" position in the myelofibrosis landscape and \"significant\" commercial potential, Euroz Hartleys said in a Thursday note.Myelofibrosis is a b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620941432","title":"Syntara Receives Nearly AU$2 Million Milestone Payment from UK Charity","url":"https://stock-news.laohu8.com/highlight/detail?id=2620941432","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620941432?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:19","pubTimestamp":1773883147,"startTime":"0","endTime":"0","summary":"Syntara  received a milestone payment of about AU$1.7 million from Parkinson's UK following the dosing of the final patient in its second-phase clinical trial of SNT-4728, a potential treatment targeting neuroinflammation linked with early-stage Parkinson's disease, according to a Thursday filing with the Australian bourse.The trial is evaluating SNT-4728 in individuals diagnosed with isolated rapid eye movement sleep behavior disorder, one of the strongest early indicators of future Parkinson's disease and related neurodegenerative disorders, the filing said.The company will be eligible to receive a further AU$450,000 upon completion of the project, per the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNT.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605122162","title":"Syntara's Pancreatic Cancer Drug Candidate to be Subject of Australian Government-Funded Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2605122162","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605122162?lang=en_us&edition=fundamental","pubTime":"2026-01-21 12:07","pubTimestamp":1768968426,"startTime":"0","endTime":"0","summary":"Syntara  said a study to evaluate its advanced pancreatic cancer drug candidate amsulostat, or SNT-5505, in combination with standard-of-care chemotherapy will be one of the two multi-center Australian clinical studies conducted after the Garvan Institute of Medical Research in Sydney secured a AU$3 million grant under the Australian Government's Medical Research Future Fund, according to a Wednesday Australian bourse filing.The study will assess safety and clinical activity, as well as conduct deep molecular and genetic profiling of tumor and blood samples collected before and during treatment, the filing said.Both studies are expected to start recruitment in mid-2026, enrolling patients with advanced pancreatic cancer across leading cancer centers in New South Wales.The company will supply the investigational anti-fibrotic LOX inhibitor in addition to scientific and clinical expertise for the study, per the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNT.AU","XKO.AU","XAO.AU","XJO.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":24,"code":"91000000","status":"200"}]}}